Renal cell carcinoma treatment

Drug – bio-affecting and body treating compositions – Lymphokine – Interferon

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C424S085100, C424S085400, C530S351000, C530S421000, C514S002600

Reexamination Certificate

active

06605273

ABSTRACT:

BACKGROUND OF THE INVENTION
This invention relates to an improved therapy for treating patients having renal cell carcinoma (“RCC”) by administering a therapeutically effective dose of pegylated interferon-alpha for a time sufficient to achieve at least a partial tumor response.
Metastatic renal cell carcinomas are generally resistant to chemotherapy, either with single agents or in combination. Greater success has been seen with immunotherapy, particularly with the use of interleukin-2 (“IL-2”). Therapy with high dose intravenous IL-2 has resulted in objective tumor responses in approximately 14% of patients, some with long durability. The administration of high dose IL-2 is associated with capillary leak syndrome, which results in hypotension and reduced organ perfusion which can be severe and sometimes fatal. These toxicities have generally inhibited the use of IL-2 to a highly selected group of patients administered by physicians with significant experienced in its administration. The use of lower-dose and subcutaneously (SC) administered regimens of IL-2 alone or in combination with other biologic agents, including interferon-&agr;, has been explored in an effort to develop a more broadly applicable therapy for this disease. For example, Atzpodien, J., et al. disclosed in J. Clin Oncol., 1995, Volume 13, pages 497-501 that the combination treatment of subcutaneous (“SC”) administration and lower dose regimens of interferon alpha-2b and SC interleukin-2 to patients with progressive metastatic RCC produced tumor response with lower toxicity. It must be noted that the response rates are low and that injections of interferon alpha-2b 5 million IU/m
2,
three times a week (“TIW”), were required to achieve these results. In addition, interferon alpha-2b has many side effects that a substantial number of patients find unacceptable, and patient compliance with the TIW injections of interferon alpha-2b has become a problem. Accordingly, there is a need for an improved therapy for treating patients having RCC.
SUMMARY OF THE INVENTION
The present invention provides a method of treating a patient having renal cell carcinoma which comprises administering to such a patient a therapeutically effective dose of pegylated interferon alpha for a time period sufficient to effect at least a partial tumor response.
The present invention also provides a method of treating a patient having metastatic renal cell carcinoma which comprises administering to said patient an effective amount of pegylated interferon-alpha once a week for a time period sufficient to effect at least a partial tumor response.
The present invention further provides a method of treating a patient having metastatic renal cell carcinoma which comprises administering to such a patient about 4.5 micrograms/kg to about 9.0 micrograms/kg of pegylated interferon alpha-2b once a week for a time period sufficient to effect at least a partial tumor response.


REFERENCES:
patent: 4492537 (1985-01-01), Awerkamp
patent: 4530901 (1985-07-01), Weissmann
patent: 4695623 (1987-09-01), Stabinsky
patent: 4766106 (1988-08-01), Katre et al.
patent: 4897471 (1990-01-01), Stabinsky
patent: 4917888 (1990-04-01), Katre et al.
patent: 5382427 (1995-01-01), Plunkett et al.
patent: 5711944 (1998-01-01), Gilbert et al.
patent: 5762923 (1998-06-01), Gross et al.
patent: 5766582 (1998-06-01), Yuen et al.
patent: 5766897 (1998-06-01), Braxton
patent: 5776897 (1998-07-01), Lewis et al.
patent: 5908621 (1999-06-01), Glue et al.
patent: 5951974 (1999-09-01), Gilbert et al.
patent: 5985263 (1999-11-01), Lee et al.
patent: 6362162 (2002-03-01), Rybak et al.
patent: 2001/0038833 (2001-11-01), Rybak et al.
patent: 0 510 356 (1992-10-01), None
patent: 0 593 868 (1994-04-01), None
patent: 0 236 987 (1994-12-01), None
patent: 0 809 996 (1997-12-01), None
patent: WO 95/13090 (1995-05-01), None
patent: WO 98/48840 (1998-11-01), None
patent: WO 99/48535 (1999-09-01), None
Hasford et al. “Interferon-&agr; and Hydroxyurea in Early Chronic Myeloid Leukemia: A Comparative Analysis of the Italian and German Chronic Myeloid Leukemia Trials with Interferon-&agr;,” Blood 87 (12)5384-5391 (1996).
Ozer et al., “Prolonged Subcutaneous Administration of Recombinant &agr;2b Interferon in Patients with Previously Untreated Philadelphia Chromosome-Positive Chronic-Phase Chronic Myelogenous Leukemia: Effect on Remission Duration and Survival: Cancer and Leukemia Group B Study 8583,” Blood 82:10 pp. 2975-2984, Nov. 15, 1993.
Atzpodien et al., “Home therapy with recombinant interleukin-1 and interferon-&agr;2b in advanced human malignancies,” The Lancet, 335, pp. 1509-1512 (1990).
Cascinelli et al., “Results of adjuvant interferon study in WHO melanoma programme,” The Lancet, 343:913-914, Apr. 9, 1994.
Deprés-Brummer et al., “A Phase II Study of Ambulatory Chronomodulated High Dose Interferon (IFN&agr;2a) Against Metastatic Renal Cancer (MRC),” American Society of Clinical Oncology, Abstract No. 628, 15:248, Mar. 1996.
Escudier et al., “The FNCLCC Crecy Trial: Interleukin 2 (IL2) + Interferon (IFN) is the Optimal Treatment to Induce Response in Metastatic Renal Cell Carcinoma (MRCC),” American Society of Clinical Oncology, Abstract No. 629, 15:248, Mar. 1996.
Gitlitz et al., “Fluoropyrimidines Plus Interleukin-2 and Interferon-&agr; in the Treatment of Metastatic Renal Cell Carcinoma: The UCLA Kidney Cancer Program,” American Society of Clinical Oncology, Abstract No. 630, 15:248, Mar. 1996.
Kantarjian et al., “Treatment of Chronic Myelogenous Leukemia: Current Status and Investigational Options,” Blood 87:8 pp. 3069-3081, Apr. 15, 1996.
Hehlman et al., “Randomized Comparison of Interferon-&agr; With Busulfan and Hydroxyurea in Chromic Myelogenous Leukemia,” Blood 84:12 pp. 4064-4077, Dec. 15, 1994.
Kantarjian et al., “Chronic Myelogenous Leukemia: A Concise Update,” Blood 82:3 pp. 691-703, Aug. 1, 1993.
Nicolaou et al., “Total Synthesis of Taxol. 1. Retrosynthesis, Degradation, and Reconstitution,” J. Am. Chem. Soc. 117 pp. 624-633, 1995.
Hasford, et al “Interferon-&agr; and Hydroxyurea in Early Chronic Myeloid Leukemia: A Comparative Analysis of the Italian and German Chronic Myeloid Leukemia Trials With Interferon-&agr;,”.
Ozer et al., “Prolonged Subcutaneous Administration of Recombinant &agr;2b Interferon in Patients with Previously Untreated Philadelphia Chromosome-Positive Chronic-Phase Chronic Myelogenous Leukemia: Effect on Remission Duration and Survival: Cancer and Leukemia Group B Study 8583,” Blooc 82:10 pp. 2975-2984, Nov. 15, 1993.
Ohnishi et al., “A Randomized Trial Comparing Interferon-&agr; With Busulfan for Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase,” Blood 86:3 pp. 906-916, Aug. 1, 1995.
Creagon et al., “Randomized, Surgical Adjuvant Clinical Trial of Recombinant Interferon Alfa-2a in Selected Patients With Malignant Melanoma,” Journal of Clinical Oncology, 13:13 pp. 2776-2783 Nov. 1995.
Bergmann et al., “Daily Alternating Administrationn of High-Dose Alph-2b-Interferon and Interleukin-2 Bolus Infusion in Metastatic Renal Cell Cancer,” Cancer 72:5, pp. 1735-1742 Sep. 1, 1993.
Umeda et al., “Phase II Study of Alpha Interferon on Renal Cell Carcinoma,” Cancer 58:1231-1235, Sep. 15, 1986.
Sokal et al., “Preferentiall Inhibition by Cytarabine of CFU-GM From Patients With Chronic Granulocytic Leukemia,” Cancer 59:197-202, Jan. 1, 1987.
Fleming et al., “One-Sample Multiplel Testing Procedure for Phase II Clinical Trials,” Biometrics 38:143-151 Mar. 1982.
Rosenberg, et al., “Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients,” Ann. Surg. 210:4 pp. 475-485.
Kantarjian et al., “Prolonged Survical in Chronic Myelogenouos Leukemia after Cytogenetic Response to Interferon-&agr; Therpay,” Ann Intern Med. 122:254-261, 1995.
Talphaz et al., “Interferon-Alpha Produces Sustained Cytogenetic Responses in Chronic Myelogenouos Leukemia,” Annals of Internal Medicine, 114:7 Apr. 1, 1991.
Négrier et al., “Intensive Regimen of Cytokines with Interleukin-2 and Interferon Alfa-2B in Selected Patients with Metastatic Renal Car

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Renal cell carcinoma treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Renal cell carcinoma treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Renal cell carcinoma treatment will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3112212

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.